Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03967223 · ClinicalTrials.gov registry record · Phase 2
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors
A Phase 2 study of Neoplasms, sponsored by Uswm CT.
- Active
- Registry status
- Phase 2
- Development phase
- 103
- Enrollment target
- 20
- Study locations
NCT03967223: Active Phase 2 study of Neoplasms, sponsored by Uswm CT.
NCT03967223 is a Phase 2 study of Neoplasms that is active but no longer recruiting, run by Uswm CT. The registered enrollment target is 103 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03967223, a Phase 2 study of Neoplasms, is active but no longer recruiting, sponsored by Uswm CT.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 103 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors.
Primary Outcome
Overall response rate is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) relative to the total number of participants within the analysis population at any time per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. as determined by the local investigators.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Letetresgene autoleucel (lete-cel, GSK3377794)
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- Stanford Hospital and Clinics - Stanford
Massachusetts
- Dana Farber Cancer Institute - Boston
- Massachusetts General Hospital - Boston
Minnesota
- Minnesota Oncology Hematology - Minneapolis
- Mayo Clinic Rochester - Rochester
Texas
- University Of Texas Southwestern Medical Center - Dallas
- University of Texas Southwestern Medical Center - Dallas
Colorado
- Sarah Cannon Research Institute - Denver
Florida
- Mayo Clinic Jacksonville - Jacksonville
Illinois
- University of Chicago - Chicago
Iowa
- University of Iowa College of Medicine - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2019-12-31 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 2 |
What the registry record for NCT03967223 still lists
NCT03967223 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT03967223 names 20 study sites across 16 states, led by California, Massachusetts, Minnesota.
Frequently Asked Questions
What is clinical trial NCT03967223 about?
NCT03967223 is a clinical study titled "Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors". This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors.
What is the current status of trial NCT03967223?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2019-12-31. Estimated completion is 2026-07-31.
What conditions does trial NCT03967223 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT03967223?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Letetresgene autoleucel (lete-cel, GSK3377794) (DRUG).
Who is sponsoring clinical trial NCT03967223?
This trial is sponsored by Uswm CT, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03967223 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03967223's enrollment target sits among peer trials
103 70th of 158 higher than 89 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
RECRUITING · Phase 2
-
Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue
RECRUITING · Phase 2
-
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
RECRUITING · Phase 2
-
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
RECRUITING · Phase 2
-
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04690348 · 103 participants · Phase 2
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
- NCT05282277 · 103 participants · Phase 4
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
- NCT05566769 · 103 participants · NA
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
- NCT05834478 · 103 participants · Phase 3
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI